Skip to main content

Table 2 Age-specific effectiveness and patients’ characteristics

From: Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center

Variable and category (reference)

65 to < 70 years

70 to < 75 years

 ≥ 75 years

p value of interaction term with age category

Case

(n = 30)

Control

(n = 974)

Case

(n = 44)

Control

(n = 1,085)

Case

(n = 90)

Control

(n = 1,995)

PPSV23 (vs. absent)

4 (13.3)

94 (9.7)

1 (2.3)

97 (8.9)

1 (1.1)

123 (6.2)

0.090

 Crude odds ratio (95% CI)

1.44 (0.49–4.22)

0.24 (0.03–1.74)

0.17 (0.02–1.24)

 Adjusted odds ratioa (95% CI)

1.34 (0.45–4.02)

0.22 (0.03–1.59)

0.17 (0.02–1.20)

0.102

Male (vs. female)

19 (63.3)

585 (60.1)

33 (75.0)

696 (64.2)

61 (67.8)

1244 (62.4)

0.736

Smoking (vs. non-smokers)

      

0.727

 Current smokers

21 (70.0)

522 (53.6)

33 (75.0)

578 (53.3)

54 (60.0)

968 (48.5)

 Ex-smokers

5 (16.7)

215 (22.1)

4 (9.1)

222 (20.5)

10 (11.1)

351 (17.6)

Chronic respiratory diseases

       

 Asthma (vs. absent)

5 (16.7)

180 (18.5)

11 (25.0)

189 (17.4)

14 (15.6)

316 (15.8)

0.506

 COPD (vs. absent)

6 (20.0)

210 (21.6)

16 (36.4)

282 (26.0)

20 (22.2)

467 (23.4)

0.360

 Lung cancer (vs. absent)

9 (30.0)

415 (42.6)

19 (43.2)

409 (37.7)

17 (18.9)

770 (38.6)

0.013

 Interstitial pneumonia (vs. absent)

7 (23.3)

167 (17.2)

8 (18.2)

195 (18.0)

14 (15.6)

340 (17.0)

0.646

 NTM (vs. absent)

11 (36.7)

167 (17.2)

10 (22.7)

191 (17.6)

27 (30.0)

388 (19.5)

0.405

 Others chronic respiratory diseasesb

(vs. absent)

5 (16.7)

87 (8.9)

4 (9.1)

118 (10.9)

28 (31.1)

332 (16.6)

0.218

Diabetes (vs. absent)

9 (30.0)

253 (26.0)

26 (59.1)

350 (32.3)

30 (33.3)

606 (30.4)

0.036

Chronic heart disease (vs. absent)

12 (40.0)

350 (35.9)

25 (56.8)

504 (46.5)

58 (64.4)

1036 (51.9)

0.736

Chronic kidney disease (vs. absent)

0

28 (2.9)

3 (6.8)

25 (2.3)

0

64 (3.2)

0.998

Systemic corticosteroid user (vs. absent)

15 (50.0)

311 (31.9)

26 (59.1)

363 (33.5)

24 (26.7)

515 (25.8)

0.029

  1. Bold value indicates statistical significance
  2. aThe odds ratios for PPSV23 were calculated for adjusting smoking, lung cancer, other chronic respiratory diseases, and systemic corticosteroid user
  3. bOther chronic respiratory diseases included chronic pulmonary aspergillosis, old pulmonary tuberculosis, sarcoidosis, and chronic cough
  4. CI, confidence interval; COPD, chronic obstructive pulmonary disease; NE, not evaluated; NTM, non-tuberculous mycobacteriosis; PPSV23, 23-valent pneumococcal polysaccharide vaccine